THE NEXT REVOLUTION IN CELL THERAPY
Allogene is developing allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapy to find the next immunologic breakthrough in cancer. That’s how we’re leading today, creating tomorrow.
THE NEXT REVOLUTION IN CELL THERAPY
Allogene is developing allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapy to find the next immunologic breakthrough in cancer. That’s how we’re leading today, creating tomorrow.
LEADING THE FUTURE OF CELL THERAPY WITH OUR AlloCAR T™ PLATFORM
INNOVATION
- Multiplex gene-engineering and gene-editing capabilities
- Proprietary lymphodepletion platform
- State-of-the-art manufacturing
- Opportunity for product optimization
PIPELINE
- CD19
- ALLO-501A – Phase 1
- BCMA
- ALLO-715 – Phase 1
- ALLO-715 + nirogacestat – Phase 1
- ALLO-605 – Phase 1
- CD70
- ALLO-316 – Phase 1
LEADERSHIP
- A highly experienced management team that includes key pioneers of CAR T cell therapy
- Approximately 275 employees singularly focused on the development of AlloCAR T™ therapy
- Allogene is proud to have approximately 50% of our senior leadership team and entire organization identify as female
WE DON’T JUST SEE THE FUTURE.
WE KNOW HOW TO GET THERE.
Our mission is to create and lead the next revolution in cancer treatment by delivering to patients the first allogeneic CAR T cell (AlloCAR T™) therapies for blood cancers and solid tumors
WHY ALLOGENEIC CELL THERAPY HAS THE POTENTIAL TO LEAD THE REVOLUTION
ACCESS
- Potential to treat all
eligible patients - Repeat dosing, if needed
- No need for complex logistics
COST
- Scalable and efficient manufacturing
- Potential to treat 100+ patients from a single manufacturing run
- Lower ancillary costs of care
SPEED/RELIABILITY
- Off-the-shelf for on-demand treatment
- Less product variability, made from healthy T cells
OUR VIRTUAL EXHIBIT
This is a virtual environment with interactive information on the latest advances in AlloCAR T™ therapy as well as our pipeline, clinical trials, and online resources.
OUR PARTNERS
